An end-to-end population genomics platform
From recruitment support to Exome+® sequencing to return of results, we enable you to bring the power of genomics to your communities.
A panel-grade clinical exome
The Exome+ assay delivers the benefits of a targeted panel, the breadth of a microarray, and the completeness of an exome
all from one assay
Genomics research platform
The Helix platform, with its dedicated clinical and research teams, supports you in delivering actionable genetic insights and conducting large-scale genetic analyses
Sequence once, query often
Helix sequences and securely stores Exome+ data on behalf of each participant enabling flexible and on-demand access to genomic data, with the proper consent
Advancing population genomics
The Healthy Nevada Project
Learn how we’re working with Renown Health to improve health outcomes
The Helix Research Platform
Enabling genomic research at a scale and depth not previously possible
POWERED BY HELIX
Projects powered by Helix
See what we’re enabling for our partners
Privacy is one of our top priorities.
We won’t share data without a participant’s permission. We pledge to uphold the highest standards of bioethics and maintain rigorous policies and procedures to keep data safe and secure.
An all in one assay
The Exome+ assay provides a clinical exome enhanced by ~300,000 informative non-coding regions. Due to its custom design and proprietary bioinformatics solutions, it enables both clinical return of results and supports research applications with: >99.5% call rate at ≥20x depth for clinically relevant regions, accurate detection of >100 CYP2D6 star alleles, array-equivalent genome-wide imputation of tens of millions of high-confidence SNPs for discovery and polygenic risk scores, and coverage of the entire mitochondrial genome.
Partner with us
Helix provides the infrastructure and services to help you carry out population-scale genomic screening and research initiatives, including one of the world's largest CLIA / CAP next-generation sequencing labs. Together, we can drive earlier identification of at-risk individuals and accelerate innovative research efforts.